Tekla Capital Management LLC Ligand Pharmaceuticals Inc Transaction History

Tekla Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$89.56 - $126.72 $2.74 Million - $3.88 Million	-30,590 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$63.37 - $107.88 $656,830 - $1.12 Million	-10,365 Reduced 25.31%	30,590 $2.23 Million
Q4 2019 Feb 13, 2020	SELL	$96.94 - $113.59 $300,514 - $352,129	-3,100 Reduced 7.04%	40,955 $4.27 Million
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $1.52 Million - $1.83 Million	14,160 Added 47.37%	44,055 $5.03 Million
Q1 2019 May 14, 2019	BUY	$105.93 - $142.47 $364,928 - $490,809	3,445 Added 13.02%	29,895 $3.76 Million
Q4 2018 Feb 13, 2019	BUY	$128.36 - $272.13 $2.25 Million - $4.76 Million	17,510 Added 195.86%	26,450 $3.59 Million
Q3 2018 Nov 13, 2018	BUY	$211.18 - $274.49 $1.89 Million - $2.45 Million	8,940 New	8,940 $2.45 Million

247

17.5M

61K

7.8K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.64B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.